Passage Bio Inc (PASG) - Total Assets
Based on the latest financial reports, Passage Bio Inc (PASG) holds total assets worth $74.16 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Passage Bio Inc balance sheet quality to measure how much of total assets are equity-financed.
Passage Bio Inc - Total Assets Trend (2018–2024)
This chart illustrates how Passage Bio Inc's total assets have evolved over time, based on quarterly financial data. Check Passage Bio Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Passage Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Passage Bio Inc's total assets of $74.16 Million consist of 77.0% current assets and 23.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 36.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Passage Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Passage Bio Inc (PASG) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Passage Bio Inc's current assets represent 77.0% of total assets in 2024, a decrease from 99.8% in 2018.
- Cash Position: Cash and equivalents constituted 36.7% of total assets in 2024, down from 74.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Passage Bio Inc Competitors by Total Assets
Key competitors of Passage Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Passage Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.51 | 5.15 | 14.98 |
| Quick Ratio | 2.51 | 5.15 | 14.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $33.48 Million | $70.27 Million | $296.01 Million |
Passage Bio Inc - Advanced Valuation Insights
This section examines the relationship between Passage Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.94 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -32.0% |
| Total Assets | $102.41 Million |
| Market Capitalization | $16.94 Million USD |
Valuation Analysis
Below Book Valuation: The market values Passage Bio Inc's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Passage Bio Inc's assets decreased by 32.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Passage Bio Inc (2018–2024)
The table below shows the annual total assets of Passage Bio Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $102.41 Million | -31.97% |
| 2023-12-31 | $150.54 Million | -38.19% |
| 2022-12-31 | $243.55 Million | -31.41% |
| 2021-12-31 | $355.08 Million | +8.25% |
| 2020-12-31 | $328.01 Million | +83.64% |
| 2019-12-31 | $178.61 Million | +433.79% |
| 2018-12-31 | $33.46 Million | -- |
About Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galac… Read more